Chen Yen-Wen, Hsiao Yi-Han, Ko Hsin-Kuo, Jeng Tien-Hsin, Su Kang-Cheng, Perng Diahn-Warng
Departments of Chest Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
School of Medicine, National Yang Ming Chiao Tung University, Taipei 30010, Taiwan.
Biomedicines. 2022 Dec 14;10(12):3253. doi: 10.3390/biomedicines10123253.
Patients with asthma are treated in primary healthcare facilities (PHCFs) in Taiwan, where the asthma control status associated with acute exacerbation (AE) and use of oral corticosteroids (OCS) and short-acting β2-agonist (SABA) inhalers remains unclear. A cross-sectional, close-ended, face-to-face questionnaire survey invited board-certified physicians who treat adult asthma patients in PHCFs. The contents of the questionnaire included three parts: rescue OCS to treat AE, regular OCS for asthma control, and AE-related adverse outcomes. There were 445 out of 500 physicians who completed the questionnaire, with 61% of them being non-pulmonologists. A substantial proportion of asthma patients needed rescue OCS or regular OCS each month, or ≥3 canisters of SABA inhalers per year. Approximately 86% of physicians reported their patients with ≥2 AE-related unscheduled visits to clinics or emergency departments in the past year. A total of 41% of physicians reported their patients receiving intubation or intensive care in the past year. A total of 92% of physicians prescribed rescue OCS ≤ 40 mg/day. A total of 92% of physicians prescribed rescue OCS for a duration of ≤7 days for AEs. A total of 85% of physicians prescribed regular OCS ≤ 10 mg/day for asthma control. This is the first study to present the perceptions of asthma-treating physicians on the use of OCS in PHCFs. In summary, 31% of physicians reported ≥ 6% of their patients needed OCS for asthma control and 41% of physicians reported their patients with adverse outcomes in the past year. Thus, the need to improve asthma control in Taiwan is suggested by our study results.
台湾地区的哮喘患者在基层医疗保健机构(PHCFs)接受治疗,然而,哮喘控制状况与急性加重(AE)以及口服糖皮质激素(OCS)和短效β2激动剂(SABA)吸入器的使用之间的关系仍不明确。一项横断面、封闭式、面对面问卷调查邀请了在基层医疗保健机构治疗成年哮喘患者的获得委员会认证的医生。问卷内容包括三个部分:用于治疗急性加重的急救OCS、用于哮喘控制的常规OCS以及与急性加重相关的不良结局。500名医生中有445名完成了问卷,其中61%为非肺科医生。相当一部分哮喘患者每月需要急救OCS或常规OCS,或每年需要≥3罐SABA吸入器。约86%的医生报告称,他们的患者在过去一年中有≥2次因急性加重而进行的非计划门诊或急诊就诊。共有41%的医生报告称,他们的患者在过去一年中接受了插管或重症监护。共有92%的医生开具的急救OCS剂量≤40毫克/天。共有92%的医生为急性加重开具的急救OCS疗程≤7天。共有85%的医生为哮喘控制开具的常规OCS剂量≤10毫克/天。这是第一项展示治疗哮喘的医生对基层医疗保健机构中OCS使用看法的研究。总之,31%的医生报告称,他们≥6%的患者需要OCS来控制哮喘,41%的医生报告称他们的患者在过去一年中出现了不良结局。因此,我们的研究结果表明台湾地区有必要改善哮喘控制情况。